
Today’s Yangtze funding roundup: CNS drug, flying robot, eVTOL…
Chinese startups in central nervous system drugs, flying robots, eVTOLs and deep-sea equipment secured fresh funding.

Chinese startups in central nervous system drugs, flying robots, eVTOLs and deep-sea equipment secured fresh funding.

The real question is whether the pressure can force the entire system to operate at a higher level rather than break under it.
The initiative is the latest in Hangzhou’s effort to lower the cost of starting and running small technology businesses.
The shift reflects a broader change in China’s robotics industry: humanoids are moving from perform for audiences to doing real work.

The designation puts Pudong in charge of exploring standards and practices that could eventually be adopted across the country.
The rapid growth of QwenWork comes as China’s technology giants increasingly focus their AI firepower on workplace agents.

Chinese startups in hydrogen materials, AI marketing and immuno-diagnostics have completed fresh funding rounds.
Tmall is turning those services into standardized retail products that can be bought alongside more familiar digital goods.
The drug took about three and a half years to reach approval, far shorter than the traditional drug-development timeline.
For Linping, the bigger bet is that robotics will reward supply chains that can respond as quickly as robot designs evolve.